Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

REGN earnings analysis

Filed April 29, 2026 · Our reading of the company's report

The latest report

Regeneron's Q1 2026 results revealed revenues of $3.605 billion, a significant increase from $3.029 billion in Q1 2025, but diluted EPS of $6.75 fell short of the consensus estimate of $8.38 primarily due to an R&D…

Read full summary

Regeneron's Q1 2026 results revealed revenues of $3.605 billion, a significant increase from $3.029 billion in Q1 2025, but diluted EPS of $6.75 fell short of the consensus estimate of $8.38 primarily due to an R&D charge. The company remains optimistic about product sales, particularly for Dupixent and EYLEA, while reaffirming its full-year guidance.

Read the original on SEC.gov

Reported figures

Earnings per share
$6.75

What stood out

  • Revenue Growth

    Q1 2026 revenue increased to $3.605 billion from $3.029 billion in Q1 2025, representing a 19% year-over-year growth.

  • Dupixent Sales Surge

    The sales of Dupixent continue to drive revenues significantly, with considerable growth reported in recent months.

  • EYLEA HD® Performance

    Sales for EYLEA HD® showed strong performance, contributing positively to the overall revenue stream.

  • R&D Investments

    The company is actively investing in research and development, significant enough to impact net income.

  • Operating Cash Flow

    Operating cash flow for Q1 2026 was reported at $800 million.

  • Strong Market Position

    Regeneron maintains substantial market share in critical therapeutic areas, bolstered by recent approvals.

What to watch

  • IPR&D Charge Impact

    Regeneron incurred an IPR&D charge affecting net income, which fell to $727.2 million from $808.7 million year-over-year.

  • Falling GAAP Net Income

    Net income decreased to $727.2 million in Q1 2026 from $808.7 million in Q1 2025, indicating pressure on profitability.

  • EYLEA® Sales Decline

    There is potential risk related to declining EYLEA® sales as competition in the ophthalmology market intensifies.

Management's outlook

Regeneron reaffirmed its guidance for 2026, indicating stability in revenue expectations despite current challenges.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.